SQZ Biotechnologies Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SQZB research report →
Price Chart
About the company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.
- CEO
- Howard Bernstein
- IPO
- 2020
- Employees
- 53
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on SQZB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $707.79K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.03
- P/B
- 0.01
- EV/EBITDA
- 0.45
- Div Yield
- 0.00%
- Gross Margin
- 46.57%
- Op Margin
- -383.68%
- Net Margin
- -377.88%
- ROE
- -87.75%
- ROIC
- -81.66%
Latest fiscal year · YoY change
- Revenue
- $21.03M-22.4%
- Gross Profit
- $9.79M-39.0%
- Op Income
- $-80,684,000
- Net Income
- $-79,464,000-15.6%
- EPS
- $-2.76-10.8%
- OCF Growth
- -1.7%
- FCF Growth
- -1.6%
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 0.32
- RSI (14)
- 48
- Avg Volume
- 6.87K
No earnings-call transcripts are available for SQZB yet.
- Free Float
- 88.7%
- Shares Outstanding
- 29.49M
- Float Shares
- 26.14M
Our SQZB coverage
Recent articles, reports, and earnings notes.
No research on SQZB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SQZB report →SQZ Biotechnologies Company (OTCMKTS:SQZB) Sees Large Drop in Short Interest
defenseworld.net · Oct 12
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
businesswire.com · Feb 29
Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
businesswire.com · Feb 29
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
businesswire.com · Nov 8
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
businesswire.com · Nov 3
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
businesswire.com · Aug 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.